Competitor Analysis: Selective Estrogen Receptor Modulators

Date: January 22, 2010
Pages: 19
Price:
US$ 170.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C82709EC150EN
Leaflet:

Download PDF Leaflet

Competitor Analysis: Selective Estrogen Receptor Modulators
Product description

The present Competitive Intelligence Report about Selective Estrogen Receptor Modulators (SERM) provides a competitor evaluation in the field of small molecules selectively modulating estrogen receptor (SERM) as of January 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Selective estrogen receptor modulators (SERMs) act as estrogen receptor (ER) agonists or antagonist depending on the targeted tissue and the specific configuration of the used SERM. Effects on bone, endometrium and breast cancer are of interest. Tamoxifen is the widely investigated and most used representative of these drugs and has been introduced in treatment advanced breast cancer, in the neoadjuvant and adjuvant setting and for prevention of the disease. Other compounds are in development for breast cancer. The ongoing need for new osteoporosis therapies has led to the development of new selective estrogen receptor modulators (SERMs) with an ideal tissue selectivity profile and beneficial effects on bone without undesirable effects on the endometrium and breast.

The report includes a compilation of currently active projects in research and development of small molecules selectively modulating estrogen receptor (SERM). In addition, the report lists company-specific R&D pipelines of selective estrogen receptor modulators. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
Index
  • Selective Estrogen Receptor Modulators
  • Corporate SERM R&D Pipelines
  • About La Merie
About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations.

Skip to top


Ask Your Question

Competitor Analysis: Selective Estrogen Receptor Modulators
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: